A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

Launched by NATIONAL CANCER INSTITUTE (NCI) · Jun 10, 2021

Keywords

ClinConnect Summary

This clinical trial is looking to learn more about urinary tract cancers, including those that are common, like bladder cancer, as well as rarer types that can affect the kidney, prostate, and testicles. The goal is to gather important information that can help researchers understand these cancers better and improve treatment options for patients.

To participate, individuals must be at least 18 years old and have a confirmed diagnosis of urinary tract or genitourinary cancer. Participants will undergo a thorough screening process that includes medical history questions, physical exams, and providing blood and urine samples. They may also have imaging scans and possibly tumor biopsies to gather more information. Throughout the study, participants will receive recommendations on managing their cancer and are encouraged to ask questions. Importantly, participants will be followed for life, which means researchers will continuously monitor their health and gather data to help advance cancer care.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Participants must have histologically or cytologically confirmed urothelial or rare genitourinary cancer including but not limited to the following: small cell carcinoma of the bladder; adenocarcinoma of the bladder; squamous cell carcinoma of the bladder; plasmacytoid urothelial carcinoma; any penile cancer; any testicular cancer, sarcomatoid renal cell carcinoma; sarcomatoid urothelial carcinoma; renal medullary carcinoma or other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to micropapillary, giant cell, lipid-rich, clear cell and nested variants, large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer, testicular Sertoli or Leydig cell tumors. Any genitourinary cancer can be included at the principal investigator's discretion.
• • Age \>=18 years.
• • Ability of participant to understand and the willingness to sign a written informed consent document.
• EXCLUSION CRITERIA:
• • -Pregnancy